Objective: To assess whether resuscitation with albumin-containing solutions, compared with other fluids, is associated with lower mortality in patients with sepsis.
T he basic principles of management for patients with sepsis continue to be resuscitation, antibiotic therapy, and source control (1) . The cornerstone of the resuscitation is fluid therapy. Although there is some evidence to guide clinicians in their choice of resuscitation goals in this patient group (2) , albeit somewhat controversial (3), there is little high quality evidence to guide the choice of fluid (1) .
The Surviving Sepsis Campaign guidelines recommend the use of either crystalloid or colloid for the early resuscitation of patients with sepsis (1), a recommendation that is based largely upon the results of the saline vs. albumin fluid evaluation study, which compared the effects of fluid resuscitation with 4% human albumin or 0.9% saline (4) . While the overall results of the saline vs. albumin fluid evaluation study showed no difference in mortality in a heterogeneous population of patients who required resuscitation in the intensive care unit (ICU), a prespecified subgroup analysis of patients with severe sepsis suggested the use of albumin might be beneficial. However, there are well-known problems with drawing conclusions based upon the results of subgroup analyses (5, 6) . Previous metaanalyses that have examined the effectiveness of albumin solutions for resuscitation have concentrated on critically ill patients and subgroups of patients with burns and hypoalbuminemia (7) (8) (9) . No previous systematic review has focused on the use of albumin as a resuscitation fluid for patients with sepsis.
Therefore we performed a systematic review and meta-analysis to attempt to address the following question: For patients with sepsis, is fluid resuscitation with albumin-containing solutions, compared with other fluids, associated with lower mortality?
MATERIALS AND METHODS
Eligibility Criteria. We searched for randomized controlled trials (RCTs) that compared fluid resuscitation with albumincontaining fluids to other fluid resuscitation regimens. Eligible studies had to include human participants, with a definable population with sepsis. We included studies in which the population with sepsis was a subgroup within a larger group of patients. Studies needed to report mortality in the sepsis cohort to be eligible for inclusion in the review.
Search Strategy. The primary electronic search was conducted in MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials databases. We used medical subject heading and keyword searches for sepsis or septicemia or the systemic inflammatory response syndrome, combined with medical subject heading and keyword searches for fluid therapy or resuscitation or plasma substitute or albumins or serum albumin along with appropriate filters for RCTs (10, 11) . There was no language restriction placed on the search. Each database was searched from inception until April 10, 2010. We also searched bibliographies of relevant review articles and the included RCTs, searched the metaRegister of Controlled Trials (12) , including the Medical Editors Trials Amnesty and contacted experts in the field to identify any unpublished trials.
Study Selection. One author (AD) screened the results of the search, and full text manuscripts of all potentially eligible articles were obtained. Two authors (AD and JM) independently applied the inclusion criteria to all potentially eligible articles. Any disagreement was resolved by discussion or by consultation with a third reviewer (APD).
Validity Appraisal and Data Extraction. All included articles were appraised, independently by two authors (AD and JM) to ascertain their internal validity, with disagreements resolved by discussion or by consulting a third reviewer (APD). Each trial was assessed for the method of randomization and allocation concealment, blinding, presentation of an intention to treat analysis (13) , and loss to follow-up of Ͼ5% of patients for the primary outcome. For studies that presented a subgroup of patients with sepsis, we assessed the manuscript for evidence of an a priori definition of the subgroup and the number of subgroups reported in the RCT (14) .
The primary outcome for this analysis was all-cause mortality. When mortality was presented at more than one time point, we preferentially used the mortality at the time point with longest complete follow-up. When mortality data were not available in the primary manuscript, the authors of the study were contacted and asked to provide these data. We extracted data from the studies, including the volumes of fluid used, comparator fluid regimens, and the endpoints used to guide the administration of fluid therapy. Two reviewers (AD and JM) independently extracted data onto data forms designed specifically for the study; data were checked for accuracy by a third reviewer (APD).
Data Analysis. A fixed-effect meta-analysis was used to pool the results. Heterogeneity among the included trials was assessed by using a chi-square test and the I 2 statistic, with an I 2 statistic of Ͼ50% indicating at least moderate heterogeneity (15) . The potential for bias was assessed by inspection of a funnel plot, and Egger's statistic (16) . The results were pooled using a pooled odds ratio (OR) (17) . We assessed the effect of the concentration of albumin used (20% to 25% compared with 4% to 5%) and the population included in the study (adult or pediatric) by assessing for an interaction term in separate single covariate metaregressions. To assess the robustness of the results, we performed an analysis excluding the results of the saline vs. albumin fluid evaluation study and also used a random effects model to pool the data. We performed separate analyses comparing albumin with each of the comparator fluids groups. Following a recent announcement by Anesthesia and Analgesia (18), we conducted a sensitivity analysis in which we excluded the trials by Boldt et al (19 -24) .
We also took into account the fact that the studies included in this analysis were often subgroups of larger studies. It is well known that subgroup analyses often lack statistical power and may report spuriously positive results (6) . The correct statistical approach to the interpretation of subgroup analyses is to look for effect modification by assessing the interaction term between the treatment allocation (in this case albumin or control) and the baseline characteristic of interest (in this case the presence or absence of sepsis at the time of randomization) (25) . We extracted the p value from this test when it was reported in the primary manuscript, or we performed a logistic regression with an appropriate interaction term when the data were not available. Due to the small numbers of events in some studies, it was not possible to perform this analysis in all cases. The p values for the interaction term were then pooled using a meta-analysis of p values. The result of this analysis provides an indication of whether the effect of albumin in patients with sepsis is likely to be different from the effect in the overall populations included in the RCTs. All analyses were preformed by using STATA 10.1 (College Station, TX).
RESULTS
The initial search returned 4029 records. After examination of the titles and abstracts, there were 88 potentially eligible studies assessed for inclusion. After application of the inclusion criteria, 17 studies (4, 20 -35) that random-ized 1977 participants to receive albumin or control fluid resuscitation regimens were included in the metaanalysis. The flow of studies, including the reasons for exclusion of studies, is shown in Figure 1 .
Study Characteristics and Validity Assessment. The characteristics of the included studies are shown in Table 1 . The results of the validity assessments are shown in Table 2 .
Quantitative Data Synthesis. Mortality data were available in all 17 included studies. There was no evidence of bias on inspection of the funnel plot, shown as Appendix 1, and this was confirmed with Egger's statistic (p ϭ .86). There was no evidence of significant statistical heterogeneity, the 2 ϭ 0.73 and the I 2 ϭ 0%. The estimate of the pooled OR for mortality of patients with sepsis resuscitated with albumin-containing fluid regimens compared with control fluid regimens was 0.82 (95% confidence limits 0.67-1.0, p ϭ .047) ( Fig. 2) .
When the saline vs. albumin fluid evaluation study is omitted, the results of the pooled analysis remain similar, with an estimate of the OR for mortality of 0.84 (95% confidence limits 0.59 -1.18, p ϭ .31). Utilizing a random effects model to pool the results of all studies produces an estimate of the OR for mortality of 0.84 (95% confidence limits 0.69 -1.02, p ϭ .08). The results of the sensitivity analysis excluding the trials by Boldt et al (19 -24) , which do not alter the conclusions of our analysis, are given in an online data supplement (see Supplemental Digital Content 1, http://links.lww.com/CCM/A220). There were eight studies including 383 participants that used more concentrated (Ն20%) albumin solutions, and nine studies including 1594 participants that used more dilute solutions (4%, 4.5%, or 5%). The pooled estimate of the OR for death in studies that used concentrated albumin solutions was 1.08 (95% confidence limits 0.7-1.68, p ϭ .73), and the pooled estimate of the OR in studies that used more dilute albumin solutions was 0.76 (95% con-fidence limits 0.61-0.95, p ϭ .02). The p value for the interaction for albumin concentration was 0.09. There were three studies including 248 participants in studies in pediatric populations. The estimate of the pooled OR for the effect Table 3 summarizes the pooled estimate of the effect of albumin on mortality compared with each of the comparator fluid in patients with sepsis.
To address the question of whether there is evidence that the effect of albumin is different in patients with and without sepsis, a meta-analysis of p values was performed. Nine studies reported a subgroup of participants with sepsis. Meta-analysis of p values for these nine studies gives an overall p ϭ .67, indicating no significant evidence that the effect of albumin on mortality is different in patients with sepsis compared with the overall results of the included studies.
DISCUSSION
We performed a systematic review and meta-analysis to investigate the relationship between the use of albumin-containing fluids as a resuscitation fluid and mortality in septic patients. We found 17 trials including 1977 septic patients who were randomized to resuscitation that included albumin solutions. The trials often only included patients with sepsis as a subgroup of the total populations studied, and the methodological quality of the studies was variable. We found evidence that suggests that albumin reduces mortality when used as a resuscitation fluid for patients with sepsis. The overall estimate of treatment was consistent when the largest study was removed from the analysis. There are a number of possible mechanisms by which albumin could have a beneficial effect in patients with sepsis. As much of the beneficial effect of albumin was in comparison with resuscitation with crystalloid, it is possible that the effect was due to the additional intravascular volume expansion that albumin provides compared with crystalloids, even though the resuscitation targets were similar. Additional to volume expansion effects, albumin has an important physiologic role as a transporter of biologically active molecules, as a drug binder, in the maintenance of colloid osmotic pressure, and in maintaining the permeability of the capillary membrane, in the inhibition of platelet aggregation, and as a freeradical scavenging antioxidant (36, 37) . Restoration of physiologic levels of serum albumin may allow these functions to continue and provide benefits to patients with sepsis; the antioxidant function in particular may be crucial in the pathophysiology of sepsis (37) . However, although there are theoretical advantages to maintaining serum albumin within the normal range, high quality evidence that supplementing albumin in critically ill patients is beneficial is currently lacking (38) .
There are a number of limitations to our analysis. As with all meta-analyses, the results of the overall pooled analysis are only as reliable as the results of the included studies. In this analysis, the methodological quality of the included studies was often not optimal. Although the p value for the primary analysis was statistically significant, when a random effects model was used to pool the data, the p value fell short of the traditional level of statistical significance, casting some doubt on the robustness of the analysis. The other major limitation to drawing strong conclusions from these data are that the included studies often included only a subgroup of patients with sepsis. Given that the p value for the interaction test returned a statistically nonsignificant result, it may be that the effect of albumin in patients with sepsis is not different to the overall effect of albumin in patients who require resuscitation, that is, it may not have an effect on mortality. The data to evaluate other outcomes and potential adverse effects of albumin or to assess the impact of timing of administration were not available in the studies included in the meta-analysis, nor were the data available to evaluate the economic implications of using albumin as a resuscitation fluid for all patients with sepsis.
The results of this analysis are different from those of previous meta-analyses of albumin in the critically ill (8, 9) . This analysis has focused on a more specific population, rather than the heterogeneous populations included in previous studies. It may also be that the results of this analysis are a chance finding; they certainly need to be confirmed in further adequately powered, well-conducted RCTs. It is well known that the results of meta-analyses may be refuted by subsequent adequately powered RCTs (39) .
Further research will be needed before definitive recommendations can be made regarding the optimal choice of fluid for resuscitation of patients with sepsis. There are currently at least three ongoing randomized trials of albumin in patients with sepsis. The Efficacy of Albumin Administration for Volume Replacement in Patients with Severe Sepsis or Septic Shock-the ALBumin Italian Outcome Sepsis study (NCT00707122) plans to enroll 1350 patients and to finish May 2010. The Multicenter, Early Albumin Resuscitation During Septic Shock study (NCT00327704) completed enrolment of 800 patients in March 2010. The Five Percent Albumin vs. Normal Saline as Fluid Resuscitation Strategies for the Management of Early Suspected Septic Shock (NCT00819416) study completed enrollment of 47 patients in February 2010. The results of these studies should provide further guidance as to the optimal fluid for the resuscitation of patients with sepsis.
The results of this meta-analysis suggest that resuscitation with albumin may result in lower mortality compared with resuscitation with other fluids. Until additional data are available, clinicians may consider albumin as a first line resuscitation fluid for patients with sepsis. 
